



HAL
open science

Towards Long Wavelength Absorbing Photodynamic Therapy Photosensitizers via the Extension of a [Ru(bipy) ₃] ²⁺ Core

Johannes Karges, Olivier Blacque, Philippe Goldner, Hui Chao, Gilles Gasser

► **To cite this version:**

Johannes Karges, Olivier Blacque, Philippe Goldner, Hui Chao, Gilles Gasser. Towards Long Wavelength Absorbing Photodynamic Therapy Photosensitizers via the Extension of a [Ru(bipy) ₃] ²⁺ Core. European Journal of Inorganic Chemistry, 2019, 2019 (32), pp.3704-3712. 10.1002/ejic.201900569 . hal-02273765

HAL Id: hal-02273765

<https://hal.science/hal-02273765>

Submitted on 29 Aug 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Towards Long Wavelength Absorbing Photodynamic Therapy

Photosensitizers via the Extension of a $[\text{Ru}(\text{bipy})_3]^{2+}$ Core

Johannes Karges,^[a] Olivier Blacque,^[b] Philippe Goldner,^[c] Hui Chao,^[d] and Gilles Gasser^{[a],*}

Abstract: Complementary to classical treatment methods used against cancer, photodynamic therapy (PDT) has received increased attention over the last years. PDT relies on the generation of reactive oxygen species (ROS) upon light irradiation to trigger cell death. As the wavelength employed during such treatments directly influences the light penetration depth and therefore the possibility to treat deep seated tumours or large tumours, research efforts have been made towards the development of photosensitizers (PS) with an absorption in the phototherapeutic window (600–900 nm). To tackle this drawback, we report herein the preparation and characterisation of new Ru(II)-containing PDT PSs, that are based on a $[\text{Ru}(\text{bipy})_3]^{2+}$ core (**1**; bipy: 2,2'-bipyridine) and that are extended with methyl groups (**2**) or vinyl dimethylamino groups (**3**). As anticipated with our design, we found a red-shift of 65 nm of the maximum absorption of complex **3** in comparison to complex **1**. In addition, we report on the in-depth photophysical properties as well as (photo-)cytotoxicity against cervical cancerous HeLa cells of the investigated compounds.

Introduction

Over the last decades, cancer has emerged to be one of the deadliest diseases worldwide.^[1] Next to the classical treatments (e.g., chemotherapy, surgery and radiotherapy), the use of Photodynamic Therapy (PDT) has received increased attention

as a complementary medical technique to these blockbusters. PDT is based on the combination of light, a photoactive compound called a Photosensitizer (PS) and oxygen. Ideally, the PS should be nontoxic in the absence of light and generate highly toxic species upon light irradiation. The mechanism of action of PDT is based on the generation of reactive oxygen species (ROS). More specifically, upon light irradiation, the PS is excited to a singlet state, which can be transformed into an excited triplet state by an intersystem crossing (ISC) process. From there, the PS is able to influence its biological environment by two pathways, namely Type I and Type II. During a Type I reaction, an electron or proton is transferred to/from the PS from/to its biological surrounding. This leads to the generation of radicals and ROS like superoxides or hydroxyl radicals. In a Type II reaction, the energy of the excited triplet state of the PS is transferred to molecular oxygen ($^3\text{O}_2$) to produce singlet oxygen ($^1\text{O}_2$). This highly energetic form of oxygen is highly reactive. Consequently, during both pathways, ROS or $^1\text{O}_2$ react with its biological surrounding, generating cellular damages and therefore ultimately trigger cell death.^[2]

The most commonly used PS for PDT treatments is Photofrin (Figure 1), which is approved for the treatment of bladder cancer, early stage lung cancer, oesophageal cancer and early non-small cell lung cancer in various countries. To date, the majority of approved PSs are based on a tetrapyrrolic scaffold. Due to their relatively similar structures, the majority of these compounds have a tendency to share the same disadvantages, which are 1) poor water solubility; 2) tedious synthesis; 3) photobleaching effect and 4) slow clearance from the body causing photosensitivity. At this stage, it is important to mention that some compounds based on a tetrapyrrolic scaffold do not share these limitations.^[2c, 3]

[a] J. Karges, Dr. G. Gasser
Chimie ParisTech, PSL University, CNRS, Institute of Chemistry for Life and Health Sciences, Laboratory for Inorganic Chemical Biology, 75005 Paris, France.
gilles.gasser@chimieparistech.psl.eu; www.gassergroup.com

[b] Dr. O. Blacque
Department of Chemistry, University of Zurich,
Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.

[c] Dr. P. Goldner
Chimie ParisTech, PSL University, CNRS, Institut de Recherche de Chimie Paris, 75005 Paris, France.

[d] Prof. H. Chao
MOE Key Laboratory of Bioinorganic and Synthetic Chemistry,
School of Chemistry, Sun Yat-sen University, 510275 Guangzhou,
People's Republic of China.




Figure 1. Structure of a) Photofrin and b) TLD-1433. $[\text{Ru}(\text{dmb})_2(\text{IP-TT})]^{2+}$ (dmb=4,4'-dimethyl-2,2'-bipyridine, IP-TT=2-(2',2'':5'',2''-terthiophene)-imidazol[4,5-f][1,10]phenanthroline).

To tackle these drawbacks, new classes of PDT PSs are currently being developed. Among the different classes, Ru(II) polypyridyl complexes seem to be excellent candidates. The majority of these compounds have generally a high water solubility, long luminescence decay, high $^1\text{O}_2$ production as well as a high chemical and photophysical stability.^[4] Therefore, it is not surprising that the complex TLD-1433 (Figure 1, $\lambda_{\text{ex}} = 525 \text{ nm}$, $\epsilon_{\text{max}} = 2000 \text{ M}^{-1} \text{ cm}^{-1}$, $\Phi \sim 0.99$ in CH_3CN) has just completed phase I clinical trial as a novel PDT PS for the treatment of bladder cancer.^[4h, 5]

To date, most studied Ru(II) polypyridyl complexes lack significant absorption in the phototherapeutic window (600-900 nm).^[6] It is well-established that the wavelength used during treatments directly correlates with the tissue penetration depth. Longer wavelengths are able to penetrate deeper in the tissue and are hence potentially able to treat deeper-seated tumours or larger tumours. Additionally, as longer wavelengths are less energetic, less photodamage caused by the light source has been associated with treatments at longer wavelengths. Based on this, PSs with an absorption at wavelengths in the phototherapeutic window are sought after.^[7]

With the aim to develop Ru(II) polypyridyl complexes with a red-shift absorption in view of applications as PDT PSs, we have extended the parent complex $[\text{Ru}(\text{bipy})_3]^{2+}$ (**1**) (bipy = 2,2'-bipyridine) with methyl groups (**2**) and the conjugated system with vinyl dimethylamino groups (**3**) (Figure 2). Recent investigations

have shown that the π -extension of the bipy core of the Ru(II) polypyridine complex caused a red shift of the absorption of the resulting complex.^[8] In addition, previous systematic studies of differently substituted Ru(II) polypyridine complex have indicated that dialkylamino substituents strongly promote a desired red shift in absorption.^[9] Combining these concepts, we report here compound **3**, with an extended π -system and dimethylamine groups, which was indeed found to have a red-shifted absorption of 65 nm in comparison to complex **1** and an absorption in the phototherapeutic window as well as highly increased extinction coefficients. Importantly, we could show the ability of this compound to produce $^1\text{O}_2$ at longer wavelengths as well as to cause phototoxicity at this wavelength in cancerous cells while having no observed dark toxicity.




Figure 2. Chemical structures of the investigated compounds in this study. The complexes were isolated as PF_6 salts.


Results and Discussion

Synthesis and Characterisation

The complexes synthesised in this work are shown in Figure 2. Compound **1** was obtained from a commercial source whereas **2** was synthesised as previously reported by complexation of $\text{RuCl}_2\text{dmsO}_4$ with 4,4'-dimethyl-2,2'-bipyridine.^[10] To the best of our knowledge, the synthesis the complex **3** has not been yet reported. The ligand (*E,E'*)-4,4'-bis(*N,N*-dimethylaminovinyl)-2,2'-bipyridine present in complex **3** was synthesised as previously reported.^[11] However, complexation attempts of this ligand using similar conditions to complex **2** (e.g. in EtOH or DMF as well as addition of AgBF_4 to remove the Cl ligands by precipitation of AgCl) were unsuccessful. Based on these findings, the synthetic procedure was changed (Scheme 1). As the first step, the complexation of $\text{RuCl}_2\text{dmsO}_4$ with 4,4'-dimethyl-2,2'-bipyridine was performed. In a second step, an enamination reaction with *tert*-butoxy bis(dimethylamino)methane (Bredereck reagent) was

FULL PAPER

accomplished to obtain the desired compound **3**. The signals in the NMR for **3** were correlated to their protons/carbons in the structure (numbering of the complex can be found in Figure S1) via 2D-NMR (Figures S4 and S5). The identity of complex **3** was confirmed by ^1H - and ^{13}C -NMR, ESI-HRMS (Figure S2, S3, S6) and the purity of all compounds verified by elemental analysis.



Scheme 1. Synthesis of complexes **2** and **3**. a) 4,4'-dimethyl-2,2'-bipyridine, DMF, reflux, 12 h, nitrogen atmosphere, 92%; b) *tert*-butoxy bis(dimethylamino)methane, DMF, 140°C, 40 h, nitrogen atmosphere, 85%.

X-ray crystallography

The crystal structures of 4,4'-bis(*N,N*-dimethylaminovinyl)-2,2'-bipyridine and **2** have been determined by single crystal X-ray diffraction studies. Crystal data, structure refinement parameters and molecular structures are presented in Table S1 as well as Figures 3 and S7. The crystal structure of 4,4'-bis(*N,N*-dimethylaminovinyl)-2,2'-bipyridine presented in the manuscript is a new monoclinic polymorph (**a**) of the previous structure (**b**) reported by Viau et al. in 2003.^[12] The asymmetric unit in **a** contains one and a half molecules: one of the independent molecules lies on a center of inversion located in the middle of the central C – C bond while the second one occupies a general position. In both polymorphs the bipyridine derivative exhibits a classical *transoid* arrangement due to the repulsion of the nitrogen lone pairs and a *E* configuration of the enamine double bonds. Polymorphs **a** and **b** significantly differ from each other in the relative orientation of the C=C double bonds of the enamine moieties with the central rings. Indeed, in **a** they adopt a *s-trans* conformation with respect to C3-C4, C12-C13 and C20-C21 (Figure S7) while in **b** a *s-cis* conformation is observed (see Figure S8). In our crystals the molecules are linked by C—H...N and C—H... π interactions. In the structure of the trisbipyridyl ruthenium(II) complex **2** the central Ru atom is expectedly coordinated to the six nitrogen atoms of the three substituted bipyridines in a distorted octahedral geometry. The complex cations crystallized with PF_6^- counter-ions and solvent molecules of diethyl ether in a ratio 1/2/1. It is interesting to note that the

crystal structure of **2** is isostructural with the previously reported crystal structure of the iron complex $[\text{Fe}(4,4'\text{-dimethyl-2,2'\text{-dipyridyl)}_3][\text{PF}_6]_2$ (Figure S9).^[13] In the crystal, ions and solvent molecules are linked together through C—H...F and C—H...O interactions. Despite the numerous aromatic rings of complex **2** no $\pi\cdots\pi$ or C—H... π interactions are observed.




Figure 3. Molecular structure of compound **2**. The thermal ellipsoids are drawn at the 30 % probability level and all H atoms and the solvent molecule of diethyl ether are omitted for clarity.

Photophysical properties

The photophysical properties of the complexes were then evaluated to assess their potential as PDT PSs. To investigate this, we have measured the absorption of complexes **1-3** in CH_3CN (Figure 4, Table 1). Typically, Ru(II) polypyridyl complexes have, as the lowest energy absorption band, a spin-allowed metal-to-ligand charge transfer (MLCT) transition, which occurs for the prototype complex $[\text{Ru}(\text{bpy})_3]^{2+}$ **1** at 450 nm. The band at 285 nm was assigned to spin-allowed ligand-centered (LC) transition and the shoulders around 350 nm to metal-centered (MC) transitions.^[6f] The comparison between complexes **1** and **2** shows only small differences indicating that the additional methyl groups in **2** do not significantly influence the absorption properties. On the contrary, the absorption of complex **3** was highly modified with a strong increase of the extinction coefficient as well as a strong red-shift of 65 nm of the maximum of the MLCT transition caused by the extension of the π -system as well as the insertion of dimethylamine groups at the terminal end. Importantly, the absorption tail of the compound is in the desired phototherapeutic window (600-900 nm). For further investigation

of the excited state, the emission properties of the complexes were investigated upon excitation of the compounds in CH₃CN at 355 nm. The emission signal was measurable between 550-850 nm (Figure S10) with a maximum at 622 nm for complex **2** and 621 nm for complex **3**. Comparison to the standard compound **1** ($\Phi_{em} = 0.059$) shows that complex **2** has an increased emission ($\Phi_{em} = 0.083$) whereas complex **3** is only weakly emitting and could only be detected at the detection limit of our used setup. These results fit with those of a recent study which compared different 4,4'- π -conjugated[2,2']-bipyridines and which found that (*E,E'*)-4,4'-bis(*N,N'*-dimethylaminovinyl)-2,2'-bipyridine itself already had a low fluorescence quantum yield of 0.015 in dichloromethane.^[14] As an additional characterisation of the excited state, the luminescence lifetimes in degassed and air saturated CH₃CN upon excitation at 355 nm were determined (Figure S11-S13). The measured lifetimes (Table 1) were found to be in the same range as for other investigated Ru(II) polypyridine complexes.^[9] Importantly, the lifetimes of the excited state is strongly decreasing in the presence of air.

Table 1. Spectroscopic properties of the investigated complexes **1-3** in CH₃CN at room temperature. λ_{em} = emission maximum, Φ_{em} = luminescence quantum yield, τ = lifetime.

	UV/Vis λ / nm ($\epsilon / M^{-1} cm^{-1} * 10^{-3}$)	λ_{em} / nm	Φ_{em}	air	degassed
1	285 (80.8), 450 (14.6)	610	0.059	130	925
2	285 (91.8), 325 (13.3), 460 (16.6)	622	0.083	109	1024
3	295 (86.2), 385 (149.7), 515 (56.4)	621	<0.001	76	410




Figure 4. Absorption spectra of complexes **1-3** in CH₃CN.

Singlet oxygen generation

As discussed in the photophysical evaluation section, the lifetimes of the excited state of the investigated compounds are drastically decreasing in the presence of air indicating that the triplet state of the compound (³PS) is able to interact with molecular oxygen (³O₂). As the active species for most applied PSs in PDT, the production of singlet oxygen (¹O₂) is responsible for most PDT effects. To investigate the ability of our compounds to generate ¹O₂, we used two different methods, namely 1) direct by measurement of the phosphorescence of ¹O₂ or 2) indirect by measurement of the change in absorbance of a reporter molecule.^[15] The results presented in Table 2 show that compounds **1** and **2** are generating ¹O₂ decently whereas **3** generates ¹O₂ only poorly.

Table 2. Singlet oxygen quantum yields in CH₃CN and aqueous solution. Average of three independent measurements, $\pm 10\%$.

	direct 450 nm CH ₃ CN	direct 450 nm D ₂ O	indirect 450 nm CH ₃ CN	indirect 450 nm PBS	indirect 540 nm CH ₃ CN	Indirect 540 nm PBS
1	54%	21%	57%	20%	n.d. ^{a)}	n.d. ^{a)}
2	66%	25%	64%	27%	n.d. ^{a)}	n.d. ^{a)}
3	n.d.	n.d.	21%	3%	18%	2%

n.d. = not detectable.

n.d.^{a)} = not detectable due to missing absorbance at this wavelength.

(Photo-)stability

An important property of a molecule, which is envisioned to be used as a PDT PS, is its (photo-)stability. To investigate this, we have assessed the stability in organic solvents of our complexes as it was shown in previous works that this could already be problematic.^[16] For this purpose, the compounds were incubated in CH₃CN and, in time intervals (0, 1, 4, 8, 12, 24, 48 h), their UV/Vis spectra measured. During the incubation in CH₃CN, no change in the spectra for all compounds (Figure S14-S16) could be detected indicating their stability in this solvent. As a second experiment, the stability in an aqueous PBS solution was investigated. Also, here, no decomposition was observed (Figure S17-S19), proving the stability of these compounds. Finally, as a third experiment, the complexes were incubated in human plasma and the stability of the complexes identified by an HPLC analysis. As an internal standard, caffeine was used, which has already been shown to be suitable for these experiments.^[17] After 48 h incubation, the compounds were extracted from the plasma and the HPLC chromatogram before and after the incubation compared. The analysis showed that no decomposition for the compounds **1** and **2** (Figure S20-S21) occurred. On the contrary,

complex **3** was clearly transformed to a mixture of different kinds of unidentified products (Figure S22), clearly proving its decomposition. After investigation of the stability of the compounds in a biological environment, we have tested their stability upon irradiation in an air saturated CH₃CN solution while monitoring their UV/Vis spectra in constant time intervals. The stability was compared to the PS Protoporphyrin IX (PpIX), which is well known to be photodegradating. The comparison between the spectra (Figure S23-S26) shows only a small decrease in absorption for **1** and **2** indicating only a small photobleaching effect. On the contrary, the bands of **3** strongly decrease and shift, proving its decomposition upon light exposure. Consequently, the modification caused by the irradiation was investigated by NMR spectroscopy. For this purpose, a solution of **3** in CD₃CN was irradiated at 450 nm (30 min, 36.0 J/cm²) and the change in the ¹H-NMR spectrum monitored. The compound was transformed in an unidentified mixture of different compounds (see Figure S27).

Cellular Uptake

A crucial parameter for the bioactivity of a molecule is its cellular uptake. To investigate this, compounds **1-3** were incubated for 4 h in the dark in human cervical carcinoma (HeLa) cells. The amount of the metal Ru inside the cells was then determined using inductively coupled plasma mass spectrometry (ICP-MS). The results (Figure 5) show that complex **3** has a much higher uptake than **1** or **2**.




Figure 5. Comparison of the cellular uptake of complexes **1-3** after 4 h incubation in HeLa cells.

Cytotoxicity and Phototoxicity

After having assessed the chemical and photophysical properties of compounds **1-3**, their influence on cell viability in the dark and upon light irradiation was investigated. For this purpose, the compounds were incubated in non-cancerous retinal pigment epithelium (RPE-1) and HeLa cells in the dark as well as upon light irradiation at 480 nm (10 min, 3.1 J/cm²) and 540 nm (40 min, 9.5 J/cm²). The obtained IC₅₀ values were further compared with the chemotherapeutic drug cisplatin and the PS Protoporphyrin IX (PpIX) (Table 3). For all investigated complexes, no toxicity in the dark could be observed (IC₅₀ > 200 μM), which is a desired characteristic for a potential PDT PS. Disappointingly, the exposure to light had only a small effect on the cell viability for the three compounds. While no toxicity was observed for compounds **1** and **2**, compound **3** showed some phototoxicity. Of note, these findings are in agreement with a study of the [Ru(bipy)₃]²⁺ complex which showed no dark and phototoxic effect in the high micromolar range.^[18] To evaluate the ability of a compound to act as a PS, the phototoxic index (PI) is calculated as the ratio between the IC₅₀ values in the dark and upon light exposure. For compound **3**, a PI value of 1.3 at 480 nm and 1.4 at 540 nm for HeLa cells and 1.3 at 480 nm and 1.2 at 540 nm for RPE-1 cells was determined. These results demonstrate that **3** is able to have a slight phototoxic effect upon exposure to higher wavelength which is a desired characteristic for a PS. However, the obtained PI values are quite low in comparison to established PSs like PpIX. The results can be rationalised by the rather poor generation of singlet oxygen of this complex. One has also to highlight that the instability of this compound in human plasma and upon irradiation is extremely problematic and could also explain these poor biological results. Overall, the biological results obtained in this section are fitting with the ICP-MS experiments carried out which showed a much better cellular accumulation of complex **3** compared to complexes **1** and **2**.

Table 3. IC₅₀ values in the dark and upon irradiation at 480 (10 min, 3.1 J/cm²) and 540 nm (40 min, 9.5 J/cm²) for complexes **1-3** in comparison to cisplatin and Protoporphyrin IX (PpIX) on non-cancerous retinal pigment epithelium (RPE-1) and human cervical carcinoma (HeLa) cells. Average of three independent measurements. n.d. = not determinable.

	HeLa					RPE-1				
	Da rk	480 nm	PI	540 nm	PI	Da rk	480 nm	PI	540 nm	PI
1	>200	>20	n.d.	>20	n.d.	>200	>20	n.d.	>20	n.d.
2	>200	>20	n.d.	>20	n.d.	>200	>20	n.d.	>20	n.d.

3	>2 00	152 .4 ± 3.8	1. 3	146 .3 ± 4.2	1. 4	>2 00	158 .5 ± 8.1	1. 3	161 .7 ± 6.2	1. 2
PpIX	>1 00	2.5 ± 0.1	>4 0	2.1 ± 0.3	>4 8	>1 00	3.8 ± 0.1	>2 6	3.1 ± 0.1	>3 2
Cisplatin	10. 5 ± 0.8	-	-	-	-	29. 3 ± 1.4	-	-	-	-

n.d. = not determinable.

Conclusions

In this study, we aimed to shift the absorption wavelength of the MLCT transition of Ru(II) polypyridyl complexes towards the red region to enable the use of longer wavelengths during PDT treatments. This would allow for deeper tissue penetration and therefore the possibility to treat deep-seated tumours and larger tumours. For this purpose, the $[\text{Ru}(\text{bipy})_3]^{2+}$ complex was extended with methyl groups (**2**) and the conjugated system extended with vinyl dimethylamino groups (**3**). The compounds were characterized in-depth including by 2D-NMR techniques and single crystal X-ray crystallography. Whereas the photophysical properties of **2** were found to be in the same range as for the standard complex **1**, compound **3** showed a highly increased absorption as shown by the very high extinction coefficients as well as a strong red shift of 65 nm. Further analysis of the photophysical properties revealed that this compound was weakly emissive and has short excited state lifetimes. We assume that these properties are limiting the necessary energy transfer from the excited state ^3PS to molecular oxygen ($^3\text{O}_2$) to ultimately produce singlet oxygen ($^1\text{O}_2$). This probably explains the poor singlet oxygen quantum yield determined in this study for complex **3**. Investigation of the stability of the compounds revealed that complexes **1** and **2** are stable in CH_3CN , PBS and human plasma whereas **3** decomposes in human plasma as well as upon light irradiation over time. Biological evaluation on the cancerous cell line HeLa and the non-cancerous cell line RPE-1 revealed no dark toxicity for any of the investigated complexes in this study. While no toxicity upon light exposure for compounds **1** and **2** could be observed, complex **3** showed some slight phototoxicity in the high micromolar range against cervical cancerous HeLa cells and importantly no measurable dark cytotoxicity. Despite unfavourable photophysical properties, **3** showed a stronger cytotoxic effect than the two other complexes **1** and **2**. Quantification of the cellular uptake of the complexes by ICP-MS experiments rationalized this observation with complex **3** being much better taken up by HeLa cells than compounds **1** and **2**.

Overall this study demonstrates how the extension of the $[\text{Ru}(\text{bipy})_3]^{2+}$ core through methyl groups (**2**) or vinyl dimethylamino groups (**3**) effects their photophysical properties including their absorption. We are currently investigating other options to synthesise Ru(II) polypyridyl complexes with a stronger luminescence, higher production of $^1\text{O}_2$ as well as stability in a biological environment as well as upon light exposure.

Experimental Section

Materials

All chemicals were obtained from commercial sources and used without further purification. Tris(2,2'-bipyridine)ruthenium(II) hexafluorophosphate $[\text{Ru}(\text{bipy})_3][\text{PF}_6]_2$ (**1**) was bought from Sigma Aldrich. The Ru(II) precursor $\text{RuCl}_2\text{dmso}_4$ was synthesised as previously reported.^[19] The ligand (*E,E*)-4,4'-bis(*N,N*-dimethylaminovinyl)-2,2'-bipyridine present in complex **3** was synthesised as previously reported.^[11]

Instrumentation and methods

^1H and ^{13}C NMR spectra were recorded on a Bruker 500 MHz NMR spectrometer. Chemical shifts (δ) are reported in parts per million (ppm) referenced to tetramethylsilane (δ 0.00) ppm using the residual proton solvent peaks as internal standards. Coupling constants (J) are reported in Hertz (Hz) and the multiplicity is abbreviated as follows: s (singlet), d (doublet), dd (doublet of doublet). ESI-MS experiments were carried out using a LTQ-Orbitrap XL from Thermo Scientific and operated in positive ionization mode, with a spray voltage at 3.6 kV. No Sheath and auxiliary gas was used. Applied voltages were 40 and 100 V for the ion transfer capillary and the tube lens, respectively. The ion transfer capillary was held at 275°C. Detection was achieved in the Orbitrap with a resolution set to 100,000 (at m/z 400) and a m/z range between 150-2000 in profile mode. Spectrum was analyzed using the acquisition software XCalibur 2.1 (Thermo Fisher Scientific). The automatic gain control (AGC) allowed accumulation of up to 2×10^5 ions for FTMS scans, Maximum injection time was set to 300 ms and 1 μscan was acquired. 10 μL was injected using a Thermo Finnigan Surveyor HPLC system (Thermo Fisher Scientific) with a continuous infusion of methanol at 100 $\mu\text{L}\cdot\text{min}^{-1}$. Elemental microanalyses were performed on a Thermo Flash 2000 elemental analyser. For analytic HPLC the following system has been used: 2 x Agilent G1361 1260 Prep Pump system with Agilent G7115A 1260 DAD WR Detector equipped with an Agilent Pursuit XRs 5C18 (100Å, C18 5 μm 250 x 4.6 mm) Column. The solvents (HPLC grade) were millipore water (0.1% TFA, solvent A) and acetonitrile (0.1% TFA, solvent B). Inductively coupled plasma mass spectrometry (ICP-MS) experiments were carried out on an iCAP RQ ICP-MS instrument (Thermo Fisher).

Synthesis

$[\text{Ru}(4,4'\text{-Dimethyl-2,2'\text{-dipyridyl)}_3][\text{PF}_6]_2$ (**2**)

FULL PAPER

[Ru(4,4'-Dimethyl-2,2'-dipyridyl)₃][PF₆]₂ (**2**) was synthesized as previously published^[6] using RuCl₂dmsO₄. Experimental data fits with the literature. Purity of the sample was assessed by HPLC and elemental analysis. Elemental analysis calcd for C₃₆H₃₆F₁₂N₆P₂Ru (%): C 45.82, H 3.85, N 8.91; found: C 45.71, H 3.69, N 8.83.

[Ru((E,E')-4,4'-Bis(N,N-dimethylaminovinyl)-2,2'-bipyridine)₃][PF₆]₂
(**3**)

[Ru(4,4'-Dimethyl-2,2'-dipyridyl)₃][PF₆]₂ (**2**) (188 mg, 0.20 mmol, 1.0 equiv.) was dissolved in dry DMF (12 mL) under nitrogen atmosphere and tert-Butoxy bis(dimethylamino)methane (0.9 mL, 4.36 mmol, 21.8 equiv.) was added slowly. The mixture was heated at 140 °C for 40 h. The solution was then cooled down and a sat. aqueous solution of NH₄PF₆ was added. The crude product, which precipitated as a PF₆ salt was collected by filtration and washed with H₂O and Et₂O. The product was isolated via fractionated precipitation from CH₃CN by adding dropwise Et₂O. 215 mg of **3** (0.17 mmol, 85 %) were yielded as a dark red solid. ¹H-NMR (CD₃CN, 500 MHz): 7.98 (d, ⁴J = 2.0 Hz, 6H, H3), 7.45 (d, ³J = 13.4 Hz, 6H, H8), 7.24 (d, ³J = 6.2 Hz, 6H, H6), 6.90 (dd, ^{3,4}J = 6.2, 2.0 Hz, 6H, H5), 5.09 (d, ³J = 13.4 Hz, 6H, H7), 2.94 (s, 36H, H10). ¹³C-NMR (CD₃CN, 125 MHz): δ = 157.8 (C2), 150.2 (C4), 150.0 (C6), 147.0 (C8), 120.2 (C5), 116.7 (C3), 93.0 (C7), 40.9 (C10). ESI-HRMS (pos. detection mode): calcd for C₅₄H₆₆N₁₂Ru m/z [M]²⁺ 492.2283; found: 492.2284. Elemental analysis calcd for C₅₄H₆₆F₁₂N₁₂P₂Ru (%): C 50.90, H 5.22, N 13.19; found: C 50.64, H 4.96, N 12.90.

X-ray crystallography

X-ray single-crystal data were collected at low temperatures, 160(1) K for 4,4'-bis(N,N-dimethylaminovinyl)-2,2'-bipyridine and at 183(1) K for compound **2**, with an Oxford liquid-nitrogen Cryostream cooler on a Rigaku OD XtaLAB Synergy Dualflex (Pilatus 200K detector) diffractometer. A single wavelength X-ray source from a micro-focus sealed X-ray tube were used with the Cu K_α radiation (λ = 1.54184 Å)^[20] for both analyses. The selected single crystals were mounted using polybutene oil on a flexible loop fixed on a goniometer head and transferred to the diffractometer. Pre-experiments, data collections, data reductions and analytical absorption corrections^[21] were performed with the program suite *CrysAlisPro*.^[22] Using *Olex2*,^[23] the structures were solved with the SHELXT^[24] small molecule structure solution program and refined with the SHELXL2018/3 program package^[25] by full-matrix least-squares minimization on F². Molecular graphics were created using *Mercury 4.0*.^[26] The crystal data collections and structure refinement parameters are summarized in Table S1. CCDC 1914096 (for **2**) and CCDC 1914097 (for 4,4'-bis(N,N-dimethylaminovinyl)-2,2'-bipyridine) contain the supplementary crystallographic data for these compounds, and can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

Spectroscopic measurements

The absorption of the samples has been measured with a SpectraMax M2 Spectrometer (Molecular Devices). The emission was measured by irradiation of the sample in fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped optical parametric oscillator (Ekspla) at 355 nm. Luminescence was focused and collected at right angle to the excitation pathway and directed to an Acton SP-2300i monochromator (Princeton Instruments). As a detector a PI-Max 4 CCD camera (Princeton Instruments) has been used.

Luminescence quantum yield measurements

For the determination of the luminescence quantum yield, the samples were prepared in a not degassed CH₃CN solution with an absorbance of 0.1 at 355 nm. This solution was irradiated in fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped optical parametric oscillator (Ekspla) at 355 nm. The emission signal was focused and collected at right angle to the excitation pathway and directed to an Acton SP-2300i monochromator (Princeton Instruments). As a detector a XPI-Max 4 CCD camera (Princeton Instruments) has been used. The luminescence quantum yields were determined by comparison with the reference [Ru(bipy)₃]Cl₂ in CH₃CN (Φ_{em}=5.9%)^[27] applying the following formula:

$$\Phi_{em, sample} = \Phi_{em, ref} * (F_{ref} / F_{sample}) * (I_{sample} / I_{ref}) * (n_{sample} / n_{ref})^2$$

$$F = 1 - 10^{-A}$$

Φ_{em} = luminescence quantum yield, F = fraction of light absorbed, I = integrated emission intensities, n = refractive index, A = absorbance of the sample at irradiation wavelength.

Lifetime measurements

For the determination of the lifetimes, the samples were prepared in an air saturated and in a degassed CH₃CN solution with an absorbance of 0.2 at 355 nm. This solution was irradiated in fluorescence quartz cuvettes (width 1 cm) using a NT342B Nd-YAG pumped optical parametric oscillator (Ekspla) at 355 nm. The emission signal was focused and collected at right angle to the excitation pathway and directed to an Acton SP-2300i monochromator (Princeton Instruments). As a detector a R928 photomultiplier tube (Hamamatsu) has been used.

Singlet oxygen measurements

- Direct evaluation

The samples were prepared in an air saturated CH₃CN or D₂O solution with an absorbance of 0.2 at 450 nm. This solution was irradiated in fluorescence quartz cuvettes (width 1 cm) using a mounted M450LP1 LED (Thorlabs) whose irradiation, centered at 450 nm, has been focused with aspheric condenser lenses. The intensity of the irradiation has been varied using a T-Cube LED Driver (Thorlabs) and measured with an optical power and energy meter. The emission signal was focused and collected at right angle to the excitation pathway and directed to an Acton SP-2300i monochromator (Princeton Instruments). A longpass glass filter was placed in front of the monochromator entrance slit to cut off light at wavelengths shorter than 850 nm. As a detector an EO-817L IR-sensitive liquid nitrogen cooled germanium diode detector (North Coast Scientific

Corp.) has been used. The singlet oxygen luminescence at 1270 nm was measured by recording spectra from 1100 to 1400 nm. For the data analysis, the singlet oxygen luminescence peaks at different irradiation intensities were integrated. The resulting areas were plotted against the percentage of the irradiation intensity and the slope of the linear regression calculated. The absorbance of the sample was corrected with an absorbance correction factor. As reference for the measurement rose bengal ($\Phi = 76\%$)^[28] was used and the singlet oxygen quantum yields were calculated using the following formula:

$$\Phi_{\text{sample}} = \Phi_{\text{reference}} * (S_{\text{sample}} / S_{\text{reference}}) * (I_{\text{reference}} / I_{\text{sample}})$$

$$I = I_0 * (1 - 10^{-A})$$

Φ = singlet oxygen quantum yield, S = slope of the linear regression of the plot of the areas of the singlet oxygen luminescence peaks against the irradiation intensity, I = absorbance correction factor, I_0 = light intensity of the irradiation source, A = absorbance of the sample at irradiation wavelength.

Indirect evaluation

For the measurement in CH_3CN : The samples were prepared in an air-saturated CH_3CN solution containing the complex with an absorbance of 0.2 at the irradiation wavelength, *N,N*-dimethyl-4-nitrosoaniline aniline (RNO, 24 μM) and imidazole (12 mM). For the measurement in PBS buffer: The samples were prepared in an air-saturated PBS solution containing the complex with an absorbance of 0.1 at the irradiation wavelength, *N,N*-dimethyl-4-nitrosoaniline aniline (RNO, 20 μM) and histidine (10 mM). The samples were irradiated on 96 well plates with an Atlas Photonics LUMOS BIO irradiator for different times. The absorbance of the samples was measured during these time intervals with a SpectraMax M2 Microplate Reader (Molecular Devices). The difference in absorbance ($A_0 - A$) at 420 nm for the CH_3CN solution or at 440 nm a PBS buffer solution was calculated and plotted against the irradiation times. From the plot the slope of the linear regression was calculated as well as the absorbance correction factor determined. The singlet oxygen quantum yields were calculated using the same formulas as used for the direct evaluation.

Stability in CH_3CN and PBS

The stability of the compound in CH_3CN and PBS was determined by UV/Vis spectroscopy. The compound was dissolved and stored at room temperature in the dark. The absorption spectrum from 250-700 nm was recorded with a SpectraMax M2 Microplate Reader (Molecular Devices) after each time interval (0, 1, 4, 8, 12, 24, 48 h) and compared.

Stability in human plasma

The stability of the complexes was evaluated with caffeine as an internal standard, which has already shown to be suitable for these experiments.^[17] The pooled human plasma was obtained from Biowest and caffeine from TCI Chemicals. Stock Solutions of the compounds (40 μM) and caffeine (20 μM) were prepared in DMSO. One aliquot of the solutions was added to 975 μL of human plasma to a total volume of 1000 μL . Final concentrations of the compounds of 0.5 μM and caffeine of 0.25 μM were achieved. The resulting solution was incubated for 48 h at 37 °C with

continuous gentle shaking (ca. 300 rpm). The reaction was stopped after the incubation time by addition of 2 mL of methanol. The mixture was centrifuged for 45 min at 650 g at 4 °C. The methanolic solution was filtered through a 0.2 μm membrane filter. The solvent was evaporated under reduced pressure and the residue was dissolved in 1:1 (v/v) $\text{CH}_3\text{CN}/\text{H}_2\text{O}$ 0.1% TFA solution. The solution was filtered through a 0.2 μm membrane filter and analysed using an HPLC System. Based on the big differences in lipophilicity, two different HPLC methods have been used. The solvents (HPLC grade) were millipore water (0.1% TFA, solvent A) and acetonitrile (solvent B). Method M1: 0-3 minutes: isocratic 95% A (5% B); 3- 17 minutes: linear gradient from 95% A (5% B) to 0% A (100% B); 17-23 minutes: isocratic 0% A (100% B). Method M2: 0-3 minutes: isocratic 80% A (20% B); 3-17 minutes: linear gradient from 80% A (20% B) to 0% A (100% B); 17-23 minutes: isocratic 0% A (100% B). The flow rate was 1 mL/min and the chromatogram was detected at 250 nm.

Photostability

The samples were prepared in an air saturated CH_3CN solution. To measure the photostability, the samples were irradiated at 450 nm in 96 well plates with an Atlas Photonics LUMOS BIO irradiator during time intervals from 0-10 min. The absorbance spectrum from 350-700 nm was recorded with a SpectraMax M2 Microplate Reader (Molecular Devices) after each time interval and compared.

Cell culture

Human cervical carcinoma (HeLa) cells were cultured using DMEM media and retinal pigment epithelium (RPE-1) cells using DMEM/F-12 with addition of 10% FBS and 1% penstrep. The cells were cultivated and maintained at 37 °C in a cell culture incubator at 37 °C with 5% CO_2 atmosphere. Before an experiment, the cells were passaged three times.

Cellular uptake

The cellular uptake of the complex was investigated by the determination of the Ru content inside the cells. The complex with a final concentration of 25 μM (1% DMSO, v/v) was incubated for 4 h at 37 °C in the dark on a cell culture dish with a density of ca. $6 \cdot 10^6$ cells in 10 mL of media. After this time, the media was removed and the cells were washed with cell media. The cells were trypsinised, harvested, centrifuged and resuspended. The number of cells on each dish was accurately counted. Each sample was digested using a 60% HNO_3 solution overnight. Each sample was diluted to solution of 2% HNO_3 in water. The Ru content was determined using an ICP-MS apparatus and comparing the results with the Ru references. The Ru content was then associated with the number of cells.

(Photo-)cytotoxicity

The cytotoxicity of the compounds was accessed by measuring the cell viability using a fluorometric resazurin assay. The cultivated cells were seeded in triplicates in 96 well plates with a density of 4000 cells per well in 100 μL of media. After 24 h the medium was removed and the cells were

treated with increasing concentrations of the compound diluted in cell media achieving a total volume of 200 μL . The cells were incubated with the compound for 4 h. After this time, the media was removed and replaced with 200 μL of fresh medium. For the phototoxicity studies, the cells were exposed to light with an Atlas Photonics LUMOS BIO irradiator. Each well was constantly illuminated with either a 480 nm or 540 nm irradiation. During this time, the temperature was maintained constantly at 37 $^{\circ}\text{C}$. The cells were grown in the incubator for additional 44 h. For the determination of the dark cytotoxicity, the cells were not irradiated and after the medium exchange directly incubated for 44 h. After this time, the medium was replaced with fresh medium containing resazurin with a final concentration of 0.2 mg/mL. After 4 h incubation, the amount of the fluorescent product resorufin was determined upon excitation at 540 nm and measurement its emission at 590 nm using a SpectraMax M2 Microplate Reader (Molecular Devices). The obtained data was analysed with the GraphPad Prism software.

Acknowledgments

Le Conseil Régional d'Ile de France is acknowledged for providing financial support for the purchase of a 500 MHz NMR spectrometer. This work was financially supported by an ERC Consolidator Grant PhotoMedMet to G.G. (GA 681679) and has received support under the program "Investissements d'Avenir" launched by the French Government and implemented by the ANR with the reference ANR-10-IDEX-0001-02 PSL (G.G.), the National Science Foundation of China (Nos. 21525105 and 21778079 for H.C.) and the 973 Program (No. 2015CB856301 for H.C.).

Keywords: Anticancer • Bioinorganic Chemistry • Medicinal Inorganic Chemistry • Metals in Medicine • Photodynamic Therapy


- [1] a) A. Miller, B. Hoogstraten, M. Staquet, A. Winkler, *Cancer* **1981**, 47, 207-214; b) R. Siegel, C. DeSantis, K. Virgo, K. Stein, A. Mariotto, T. Smith, D. Cooper, T. Gansler, C. Lerro, S. Fedewa, *CA Cancer J. Clin.* **2012**, 62, 220-241.
- [2] a) T. J. Dougherty, C. J. Gomer, B. W. Henderson, G. Jori, D. Kessel, M. Korbek, J. Moan, Q. Peng, *JNCI: Journal of the National Cancer Institute* **1998**, 90, 889-905; b) D. E. Dolmans, D. Fukumura, R. K. Jain, *Nat. Rev. Cancer* **2003**, 3, 380-387; c) A. E. O'Connor, W. M. Gallagher, A. T. Byrne, *Photochem. Photobiol.* **2009**, 85, 1053-1074; d) J. D. Knoll, C. Turro, *Coord. Chem. Rev.* **2015**, 282-283, 110-126; e) L. Zeng, P. Gupta, Y. Chen, E. Wang, L. Ji, H. Chao, Z.-S. Chen, *Chem. Soc. Rev.* **2017**, 46, 5771-5804.
- [3] a) F. Heinemann, J. Karges, G. Gasser, *Acc. Chem. Res.* **2017**, 50, 2727-2736; b) R. Bonnett, *Chem. Soc. Rev.* **1995**, 24, 19-33; c) M. Ethirajan, Y. Chen, P. Joshi, R. K. Pandey, *Chem. Soc. Rev.* **2011**, 40, 340-362.
- [4] a) R. Padilla, W. A. Maza, A. J. Dominijanni, B. S. Winkel, A. J. Morris, K. J. Brewer, *J. Photochem. Photobiol. A: Chem.* **2016**, 322, 67-75; b) C. Mari, V. Pierroz, S. Ferrari, G. Gasser, *Chem. Sci.* **2015**, 6, 2660-2686; c) M. Jakubaszek, B. Goud, S. Ferrari, G. Gasser, *Chem. Commun.* **2018**, 54, 13040-13059; d) J. Karges, F. Heinemann, F. Maschietto, M. Patra, O. Blacque, I. Ciofini, B. Spingler, G. Gasser, *Bioorg. Med. Chem.* **2019**, 27, 2666-2675; e) J. Liu, C. Zhang, T. W. Rees, L. Ke, L. Ji, H. Chao, *Coord. Chem. Rev.* **2018**, 363, 17-28; f) F. E. Poynton, S. A. Bright, S. Blasco, D. C. Williams, J. M. Kelly, T. Gunnlaugsson, *Chem. Soc. Rev.* **2017**, 46, 7706-7756; g) J. Shum, P. K.-K. Leung, K. K.-W. Lo, *Inorg. Chem.* **2019**, 58, 2231-2247; h) S. Monro, K. L. Colón, H. Yin, J. Roque III, P. Konda, S. Gujar, R. P. Thummel, L. Lilge, C. G. Cameron, S. A. McFarland, *Chem. Rev.* **2019**, 119, 797-828; i) J. Karges, O. Blacque, M. Jakubaszek, B. Goud, P. Goldner, G. Gasser, *J. Inorg. Biochem.* **2019**, 198, 110752; j) M. Jakubaszek, J. Rossier, J. Karges, J. Delasoie, B. Goud, G. Gasser, F. Zobi, *Helv. Chim. Acta* **2019**, accepted.
- [5] a) J. Fong, K. Kasimova, Y. Arenas, P. Kaspler, S. Lazic, A. Mandel, L. Lilge, *Photochem. Photobiol. Sci.* **2015**, 14, 2014-2023; b) P. Kaspler, S. Lazic, S. Forward, Y. Arenas, A. Mandel, L. Lilge, *Photochem. Photobiol. Sci.* **2016**, 15, 481-495; c) a) C. Mari, V. Pierroz, R. Rubbiani, M. Patra, J. Hess, B. Spingler, L. Oehninger, J. Schur, I. Ott, L. Salassa, *Chem. Eur. J.* **2014**, 20, 14421-14436; b) C. Mari, V. Pierroz, A. Leonidova, S. Ferrari, G. Gasser, *Eur. J. Inorg. Chem.* **2015**, 2015, 3879-3891; c) C. Mari, R. Rubbiani, G. Gasser, *Inorg. Chim. Acta* **2017**, 454, 21-26; d) C. Mari, H. Huang, R. Rubbiani, M. Schulze, F. Würthner, H. Chao, G. Gasser, *Eur. J. Inorg. Chem.* **2017**, 2017, 1745-1752; e) H. Huang, B. Yu, P. Zhang, J. Huang, Y. Chen, G. Gasser, L. Ji, H. Chao, *Angew. Chem. Int. Ed.* **2015**, 54, 14049-14052; f) S. Campagna, F. Puntoriero, F. Nastasi, G. Bergamini, V. Balzani, in *Photochemistry and Photophysics of Coordination Compounds I* (Eds.: V. Balzani, S. Campagna), Springer Berlin Heidelberg, Berlin, Heidelberg, **2007**, pp. 117-214;
- [7] a) K. Ogawa, Y. Kobuke, *Anti-Cancer Agents Med. Chem.* **2008**, 8, 269-279; b) B. C. Wilson, W. P. Jeeves, D. M. Lowe, *Photochem. Photobiol.* **1985**, 42, 153-162.
- [8] a) C. Mari, H. Huang, R. Rubbiani, M. Schulze, F. Würthner, H. Chao, G. Gasser, *Eur. J. Inorg. Chem.* **2017**, 1745-1752; b) B. J. Coe, L. A. Jones, J. A. Harris, B. C. Bruntschwig, I. Asselberghs, K. Clays, A. Persoons, J. Garin, J. Orduna, *J. Am. Chem. Soc.* **2004**, 126, 3880-3891.
- [9] a) M. J. Cook, A. P. Lewis, G. S. McAuliffe, V. Skarda, A. J. Thomson, J. L. Glasper, D. J. Robbins, *J. Chem. Soc. Perkin Trans. II* **1984**, 1293-1301; b) A. Juris, V. Balzani, F. Barigelletti, S. Campagna, P. I. Belsler, A. Von Zelewsky, *Coord. Chem. Rev.* **1988**, 84, 85-277.
- [10] C. M. Elliott, E. J. Hershenhart, *J. Am. Chem. Soc.* **1982**, 104, 7519-7526.
- [11] K. Willinger, K. Fischer, R. Kisselev, M. Thelakkat, *J. Mater. Chem.* **2009**, 19, 5364-5376.
- [12] L. Viau, K. Senechal, O. Maury, J.-P. Guégan, P. Dupau, L. Toupet, H. Le Bozec, *Synthesis* **2003**, 2003, 0577-0583.
- [13] M. C. Carey, S. L. Adelman, J. K. McCusker, *Chem. Sci.* **2019**, 10, 134-144.
- [14] O. Maury, J.-P. Guégan, T. Renouard, A. Hilton, P. Dupau, N. Sandon, L. Toupet, H. Le Bozec, *New J. Chem.* **2001**, 25, 1553-1566.
- [15] a) J. Karges, P. Goldner, G. Gasser, *Inorganics* **2019**, 7, 4; b) Y. Ellahioui, M. Patra, C. Mari, R. Kaabi, J. Karges, G. Gasser, S. Gómez-Ruiz, *Dalton Trans.* **2019**, 48, 5940-5951.
- [16] a) M. Patra, T. Joshi, V. Pierroz, K. Ingram, M. Kaiser, S. Ferrari, B. Spingler, J. Keiser, G. Gasser, *Chem. Eur. J.* **2013**, 19, 14768-14772; b) U. Basu, J. Karges, F. Chotard, C. Balan, P. Le Gendre, G. Gasser, E. Bodio, R. Malacea Kabbara, *Polyhedron* **2019**, in press doi.org/10.1016/j.poly.2019.1002.1041; c) H. Huang, N. Humbert, V. Bizet, M. Patra, H. Chao, C. Mazet, G. Gasser, *J. Organomet. Chem.* **2017**, 839, 15-18; d) A. K. Renfrew, J. Karges, R. Scopelliti, F. D. Bobbink, P. Nowak-Sliwinska, G. Gasser, P. Dyson, *ChemBioChem* **2019**, accepted.
- [17] S. J. Bruce, I. Tavazzi, V. r. Parisod, S. Rezzi, S. Kochhar, P. A. Guy, *Anal. Chem.* **2009**, 81, 3285-3296.
- [18] J. W. Dobrucki, *J. Photochem. Photobiol. B* **2001**, 65, 136-144.
- [19] I. Bratsos, E. Alessio, *Inorg. Synth.* **2010**, 35, 148-152.
- [20] *Rigaku Oxford Diffraction* **2015**.
- [21] R. Clark, J. Reid, *Acta Crystallogr. Sect. A: Found. Crystallogr.* **1995**, 51, 887-897.
- [22] *CrysAlisPro (version 1.171.39.13a)*, *Rigaku Oxford Diffraction* **2016**.
- [23] O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard, H. Puschmann, *J. Appl. Crystallogr.* **2009**, 42, 339-341.
- [24] G. M. Sheldrick, *Acta Crystallographica Section A: Foundations and Advances* **2015**, 71, 3-8.

- [25] G. M. Sheldrick, *Acta Crystallographica Section C: Structural Chemistry* **2015**, *71*, 3-8.
- [26] C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock, G. P. Shields, R. Taylor, M. Towler, J. v. d. Streek, *J. Appl. Crystallogr.* **2006**, *39*, 453-457.
- [27] K. Nakamaru, *Bull. Chem. Soc. Jpn.* **1982**, *55*, 1639-1640.
- [28] I. E. Kochevar, R. W. Redmond, in *Methods Enzymol.*, Vol. 319, Academic Press **2000**, pp. 20-28.

WILEY-VCH

FULL PAPER

The preparation and characterisation of new Ru(II)-containing photodynamic therapy, that are based on a [Ru(bipy)₃]²⁺ core (bipy: 2,2'-bipyridine) and that are extended with methyl groups or vinyl dimethylamino groups is described. Their in-depth photophysical properties as well as (photo-)cytotoxicity against cervical cancerous HeLa cells is also reported.



**Key Topic: Metals in Medicine •
Photodynamic Therapy**

*Johannes Karges, Olivier Blacque,
Philippe Goldner and Gilles Gasser **

**Towards Long Wavelength Absorbing
Photodynamic Therapy
Photosensitizers via the Extension of
a [Ru(bipy)₃]²⁺ Core**